Rafael Sanchez-Salas

Nov 15, 2024 | jnccn.org | Liang Dong |Katherine Lajkosz |Rafael Sanchez-Salas |Cynthia Kuk

BackgroundProstate cancer (PCa) unevenly affects populations worldwide.1–3 Historically, Asia had a lower PCa incidence and mortality compared with Western countries, but this gap is narrowing.

Jan 20, 2024 | bjui-journals.onlinelibrary.wiley.com | Rafael Sanchez-Salas

Focal therapy (FT) for prostate cancer (PCa) involves using both advanced imaging and ablative techniques to precisely target and treat specific areas of clinically significant PCa within the prostate. By focusing on the index lesion rather than the entire gland, it aims to reduce side-effects often associated with more aggressive treatments [1]. In contemporary urological practice, FT represents a groundbreaking advance that fundamentally alters the field of localised PCa treatment.